<code id='23DFCCC5B9'></code><style id='23DFCCC5B9'></style>
    • <acronym id='23DFCCC5B9'></acronym>
      <center id='23DFCCC5B9'><center id='23DFCCC5B9'><tfoot id='23DFCCC5B9'></tfoot></center><abbr id='23DFCCC5B9'><dir id='23DFCCC5B9'><tfoot id='23DFCCC5B9'></tfoot><noframes id='23DFCCC5B9'>

    • <optgroup id='23DFCCC5B9'><strike id='23DFCCC5B9'><sup id='23DFCCC5B9'></sup></strike><code id='23DFCCC5B9'></code></optgroup>
        1. <b id='23DFCCC5B9'><label id='23DFCCC5B9'><select id='23DFCCC5B9'><dt id='23DFCCC5B9'><span id='23DFCCC5B9'></span></dt></select></label></b><u id='23DFCCC5B9'></u>
          <i id='23DFCCC5B9'><strike id='23DFCCC5B9'><tt id='23DFCCC5B9'><pre id='23DFCCC5B9'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:entertainment    - browse:3291
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus